Apixaban: brand names and study card

Apixaban — Direct factor Xa inhibitor (anticoagulant). Study the mechanism, listed uses and warnings from the US label on one sourced card.

Generic name: Apixaban
Brands: Eliquis
Class: Direct factor Xa inhibitor (anticoagulant)
Mechanism: Selective inhibitor of free and clot-bound factor Xa and prothrombinase, independent of antithrombin III; decreases thrombin generation.
Used for: Stroke and systemic-embolism risk reduction in adults with nonvalvular atrial fibrillation; DVT prophylaxis after hip or knee replacement in adults; Treatment of DVT or pulmonary embolism in adults; Reduction of recurrent DVT or pulmonary embolism risk in adults after initial therapy
Common side effects: Bleeding; Headache (pediatric); Vomiting (pediatric); Excessive menstrual bleeding (pediatric)
Boxed warning: Premature discontinuation raises thrombotic risk; spinal/epidural hematoma may occur with neuraxial anesthesia or puncture.
Warnings: Serious, potentially fatal bleeding; Not recommended with prosthetic heart valves; Triple-positive antiphospholipid syndrome
Interactions: Combined P-gp and strong CYP3A4 inhibitors; Combined P-gp and strong CYP3A4 inducers; Aspirin, NSAIDs, antiplatelets

Drug class families: Direct factor Xa inhibitors

Read the source label ↗

Label date: 20260424 · For learning, not clinical decisions. US label and brand information; always consult the current source.

Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.

Practice

Pronunciation

Apixaban: a-PIX-a-ban

Shared name ending: -xaban · Rivaroxaban

Pronunciation is shown for the US English generic name. A name ending is a memory cue, not a classification rule.

Other drugs in the same class

Direct factor Xa inhibitors: Rivaroxaban

Body system

Hematology · 7 Drug cards

Compare with related cards

Rivaroxaban

Same class family: Direct factor Xa inhibitors

Mechanism: Selectively inhibits free factor Xa and prothrombinase activity without antithrombin, decreasing thrombin generation.

On both cards: Used for — Stroke and systemic-embolism risk reduction in adults with nonvalvular atrial fibrillation · Common side effects — Bleeding; Vomiting (pediatric) · Warnings — Triple-positive antiphospholipid syndrome

Only on the Rivaroxaban card: Used for — Treatment of DVT or PE in adults; pediatric VTE treatment/recurrent-risk reduction is separately indicated after at least 5 days of initial parenteral anticoagulation; DVT prophylaxis in adults after hip or knee replacement; Reduction of major cardiovascular events in adults with coronary artery disease, in combination with aspirin; Reduction of major thrombotic vascular events in adults with peripheral artery disease, in combination with aspirin · Common side effects — Cough (pediatric); Gastroenteritis (pediatric) · Warnings — Serious and fatal bleeding; Prosthetic heart valves: not recommended · Interactions — Combined P-gp and strong CYP3A inhibitors; Combined P-gp and strong CYP3A inducers; Other anticoagulants

An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.

Boxed warnings on related cards

Rivaroxaban: Premature discontinuation increases thrombotic risk; spinal/epidural hematoma with neuraxial anesthesia or puncture.